The International Skeletal Metastasis Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastatic Bone Tumor
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Overall survival (OS)
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
This is a prospective, observational study designed to contribute data from patients with symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information from patients treated for symptomatic bone metastases within the International Skeletal Metastasis Registry (ISMR)
Detailed Description
The registry is designed to update a suite of clinical decision-support tools designed for use when treating patients with metastatic bone disease. The models estimate the likelihood of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for surgical decision-making.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients, age 22 or older
- •Biopsy-proven or clinically-obvious metastatic bone disease
- •Symptomatic bone lesion requiring intervention o Including, not limited to, radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic replacement, amputation, or any combination of the above.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall survival (OS)
Time Frame: Up to 24 Months post surgery
OS (in months) calculated from the date of intervention.
Secondary Outcomes
- Reoperation or retreatment for any reason(Up to 24 24 months post surgery)
- Time to reoperation or retreatment for any reason(Up to 24 months post surgery)